PharmaTimes - March 2019

In this issue, we present Alantra’s annual ranking of the 50 fastest-growing, privately owned pharma companies. Of particular note, every single company on this list has delivered annualised revenue growth in double digits, an impressive feat during the current climate of economic uncertainty. But who tops the list? Who are the greatest movers and shakers? Take a look on page 20.

Elsewhere, we consider the long-awaited NHS Long Term Plan and what the future of the heath service might look like over the next decade (p16). Where does pharma fit into this new blueprint?

We also delve into the innovations helping to change the landscape for clinical research (p28), how clinical trials are entering a radically new dimension (p31), and how pharma is wrestling with the new ‘right to be forgotten’, brought in by the GDPR last year (p38).

On page 40 is an interview with Lotte Bjerre Knudsen, inventor of diabetes drug liraglutide and scientific vice president at Novo Nordisk, who gives a fascinating insight into her role and thoughts on the sector.

Finally, PharmaTimes is gearing up to launch the 2019 Sales Awards, Marketer of the Year and Communications Team of the Year competitions – we’ll keep you posted!

I hope you enjoy the issue.

March 2019 - magazine highlights

SmartPeople: Richard Davies

Richard Davies, vice president and solutions expert at Clu...

A need to know basis

Ten months since sweeping data privacy laws came into forc...

SmartPeople: Lotte Bjerre Knudsen

PharmaTimes talks to Lotte Bjerre Knudsen, inventor of dia...

The rise of the CRO

Dr Chris Doherty discusses the rise of clinical research o...

Resistance is futile

An exciting, futuristic chapter for clinical trials has op...

Closing the gap

How seven innovations are accelerating research and bringi...

Introducing the Pharma Fast 50

PharmaTimes presents Alantra’s annual look at the fastest-...

What does the next decade hold for the NHS?

Steve How and Oli Hudson, of the Wilmington Healthcare Con...